Atlas Trials

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

Clinical trial NCT05911061 · UNKNOWN

Trial details

NCT number
NCT05911061
Sponsor
WestVac Biopharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2024-12-30
Primary completion
2025-06-30
Enrollment
4950

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.